Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

2(28.6%)

7Total

Phase 1(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03317743Phase 1Completed

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

Role: collaborator

NCT03292783Phase 1Completed

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Role: collaborator

NCT02160106Phase 1Completed

First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

Role: collaborator

NCT01746771Phase 1Completed

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Role: collaborator

NCT01819428Phase 2Terminated

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

Role: lead

NCT01718847Phase 2Completed

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

Role: lead

NCT02300467Phase 1Unknown

NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors

Role: lead

All 7 trials loaded